Journal: Drug Design, Development and Therapy
Article Title: Design and development of ICCA as a dual inhibitor of GPIIb/IIIa and P-selectin receptors
doi: 10.2147/DDDT.S169238
Figure Lengend Snippet: Antiproliferation activity in vitro, antitumor activity in vivo, and toxicity of ICCA: ( A ) cell viabilities of ICCA-treated A549, 95D, K562, and S180 cells, n=6; ( B ) tumor weight of S180 mice orally treated with 5 μmol/kg/day ICCA for 9 consecutive days, n=12; ( C ) Cr of S180 mice orally receiving 5 μmol/kg/day ICCA for 9 consecutive days, n=6; ( D ) ALT of S180 mice orally receiving 5 μmol/kg/day ICCA for 9 consecutive days, n=6; ( E ) AST of S180 mice orally receiving 5 μmol/kg/day ICCA for 9 consecutive days, n=6; ( F ) BUN of S180 mice orally receiving 5 μmol/kg/day ICCA for 9 consecutive days, n=6. Abbreviations: 95D, nonsmall cell lung cancer cell line; ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; CMCNa, carboxymethyl cellulose sodium; Cr, creatinine; DOX, doxorubicin; ICCA, 1-(4-isopropylphenyl)-β-carboline-3-carboxylic acid; K562, human myeloid leukemia; S180, ascites tumor cells; Kar, Karmen.
Article Snippet: Human myeloid leukemia cells (K562), human nonsmall cell lung cancer cells (A549), and nonsmall cell lung cancer cells (95D) were purchased from American Type Culture Collection (Manassas, VA, USA).
Techniques: Activity Assay, In Vitro, In Vivo